In the same way, to inhibit the immunosuppressive effects of IDO, IDO inhibitory drugs such as cyclophosphamide and fludarabine have been used before CAR-T-cell therapy, reporting significant tumor regression and increased survival [180]. This evidence concerns the gene IDO1 and neoplasm.